Authored by James Sheppard
The Belgian based biotech firm Complix announced that it had raised $15.5m in series B funding to develop its novel approach to protein therapeutics. Complix added a number of new investors in this round including company management, Biotech Fund Flanders and Edmond de Rothschild Investment Partners. The new investors will join a long list of current investors including Vesalius Biocapital, CRP-Sante and OMNES Capital.
Complix has been based in the Flanders Biotechnology cluster, as recently profiled by Liftstream, since its inception in 2008. Complix is currently in pre-clinical development of its platform technology called Alphabodies. Complix states that alphabodies combine the targeting abilities of antibodies with the cell-pentatrating capabilities of small molecules. Therefore they are able to moderate intracellular interaction. Complix believes that this approach will offer a new approach in the development of treatments for cancer, autoimmune diseases, CNS and metabolic diseases.
Mark Vaeck, a prominent industry entrepreneur and the former CEO of Ablynx and ActoGenix, now CEO of Complix, said in a statement ‘we have recently demonstrated that Alphabodies have the potential to address intractable intracellular disease targets including PPIs that cause cancer. The data gives us great confidence that our Alphabody platform can deliver the next generation of drugs that the pharmaceutical industry is looking for to drive growth.’